Bullet points to be explained to the patient with HR-CLL
| • HSCT has been considered as the treatment of choice for eligible patients with HR-CLL. |
| • HSCT is the only modality with documented curative potential in CLL. |
| • The advent of BCRi/BCL2a has significantly improved the treatment options for patients with HR-CLL. |
| • BCRi/BCL2a seem to be the most effective nontransplant treatment of HR-CLL available to date. |
| • In responders to BCRi/BCL2a, 2-year survival rates are estimated at 60% to 80% with HSCT and 70% to 90% with continuation on BCRi/BCL2a. |
| • Long-term efficacy of BCRi/BCL2a is unknown, but sustained disease control and cure are unlikely. |
| • Perspectives of outcome after BCRi/BCL2a failure, including the chances of salvage HSCT, are unknown. |
| • The interaction of pre-/posttransplant BCRi/BCL2a and HSCT is unknown. |
| • HSCT has a 15% to 30% NRM risk within the first 2 years and a 25% risk of chronic GVHD relevant to the quality of life. |
| • Although more information is needed, treatment-related mortality and morbidity are both likely to be significantly lower with BCRi/BCL2a compared with HSCT. |
| • HSCT has been considered as the treatment of choice for eligible patients with HR-CLL. |
| • HSCT is the only modality with documented curative potential in CLL. |
| • The advent of BCRi/BCL2a has significantly improved the treatment options for patients with HR-CLL. |
| • BCRi/BCL2a seem to be the most effective nontransplant treatment of HR-CLL available to date. |
| • In responders to BCRi/BCL2a, 2-year survival rates are estimated at 60% to 80% with HSCT and 70% to 90% with continuation on BCRi/BCL2a. |
| • Long-term efficacy of BCRi/BCL2a is unknown, but sustained disease control and cure are unlikely. |
| • Perspectives of outcome after BCRi/BCL2a failure, including the chances of salvage HSCT, are unknown. |
| • The interaction of pre-/posttransplant BCRi/BCL2a and HSCT is unknown. |
| • HSCT has a 15% to 30% NRM risk within the first 2 years and a 25% risk of chronic GVHD relevant to the quality of life. |
| • Although more information is needed, treatment-related mortality and morbidity are both likely to be significantly lower with BCRi/BCL2a compared with HSCT. |